PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.06%
Some net income increase while VET is negative at -18.56%. John Neff would see a short-term edge over the struggling competitor.
-4.24%
Negative yoy D&A while VET is 0.56%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
69.83%
Some yoy growth while VET is negative at -1000.33%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
280.60%
Less working capital growth vs. VET's 870.92%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
280.60%
Growth of 280.60% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
775.00%
Lower 'other non-cash' growth vs. VET's 2933.19%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
80.98%
Operating cash flow growth above 1.5x VET's 20.10%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
2.26%
Lower CapEx growth vs. VET's 40.69%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-487.50%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
68.42%
Purchases growth of 68.42% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-2.26%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
4.92%
Less 'other investing' outflow yoy vs. VET's 32.83%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
13.17%
Lower net investing outflow yoy vs. VET's 33.95%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.